Cargando…
Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Solid Tumors: Real-World Incidence, Risk Factors, and Prognostic Analysis
BACKGROUND: Immune checkpoint inhibitors (ICIs) have achieved acknowledged progress in cancer therapy. However, ICI-associated cardiotoxicity as one of the most severe adverse events is potentially life-threatening, with limited real-world studies reporting its predictive factors and prognosis. This...
Autores principales: | Chen, Xue, Jiang, Aimin, Zhang, Rui, Fu, Xiao, Liu, Na, Shi, Chuchu, Wang, Jingjing, Zheng, Xiaoqiang, Tian, Tao, Liang, Xuan, Ruan, Zhiping, Yao, Yu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163804/ https://www.ncbi.nlm.nih.gov/pubmed/35669482 http://dx.doi.org/10.3389/fcvm.2022.882167 |
Ejemplares similares
-
Cardiotoxicity Related to Immune Checkpoint Inhibitors: A Real-World Retrospective Analysis
por: She, Jianqing, et al.
Publicado: (2022) -
Clinical characteristics and management of immune checkpoint inhibitor-related cardiotoxicity: A single-center experience
por: Xiao, Junjuan, et al.
Publicado: (2023) -
Immune Checkpoint Inhibitors: Cardiotoxicity in Pre-clinical Models and Clinical Studies
por: Xu, Shirley, et al.
Publicado: (2021) -
Cardiotoxicity Secondary to Immune Checkpoint Inhibitors in the Elderly: Safety in Real-World Data
por: Toribio-García, Irene, et al.
Publicado: (2023) -
Cardiotoxicity induced by immune checkpoint inhibitor: The complete insight into mechanisms, monitoring, diagnosis, and treatment
por: Ganesh, Sridha, et al.
Publicado: (2022)